Treatment of psoriatic arthritis with biological agents

Czech version

Authors: J. Štolfa
Authors‘ workplace: Revmatologický ústav, Praha
Published in: Čes. Revmatol., , 2004, No. 4, p. 175-183.
Category:

Overview

Psoriatic arthritis is a potentially serious disorder leading to a significant disability in 20–30 % ofpatients. Pharmacological treatment is limited to non-steroidal anti-inflammatory drugs, sulfasalazine,methotrexate and cyclosporine A. In contrast to rheumatoid arthritis, there has not been anybiological agent registered in the Czech Republic yet. The registration is expected in 2005. Indicationcriteria and methods of monitoring of biological treatment before its assumed registration in2005 are summarized in the present paper.

Key words:
psoriatic arthritis, biologic treatment, standard methods

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

Treatment of inflammatory rheumatic disorders in pregnancy and lactation

Cardiovascular and renal safety of coxibs

Safety and officacy of vaccination in patiens with inflammatory rheumaticdiseases

Recommendations for preventionand treatment of glucocorticoid-induced osteoporosis in patients with rheumatic disorders

Article was published in

Czech Rheumatology

2004 Issue 4